Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck is paying $700 million upfront and up to $600 million in milestones to acquire global rights to CN201, a CD19xCD3 bispecific T-cell engager, from China's…
Merck is acquiring global rights to CN201, a CD19xCD3 bispecific antibody, from Shanghai-based Curon Biopharmaceutical for $700 million upfront and up to…
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (October 1, 2024).
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Merck entered a definitive agreement to acquire global rights to CN201 from Curon Biopharmaceutical for $700M upfront plus up to $600M in milestones contingent on development and regulatory approval. The acquisition was completed on October 1, 2024 (Merck recorded a pre-tax charge of ~$750M reflecting the upfront payment and related costs). CN201 is a CD3xCD19 bispecific T-cell engager in Phase 1 for r/r NHL and Phase 1b/2 for r/r B-ALL, with potential in B-cell autoimmune diseases. Top-25 pharma buyer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. (this deal) | 2024 | $1.3B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2024 deals · Merck & Co. Inc. deals · Hematology deals